Apixaban is a direct oral anticoagulant (DOAC) — a Factor Xa inhibitor used for stroke prevention in atrial fibrillation and for VTE treatment. Key teaching: (1) bleeding precautions and red-flag reporting (unusual bruising, dark stools, blood in urine, severe headache) — choice 2; (2) hold before dental and surgical procedures per provider; (3) take twice daily as scheduled. Unlike warfarin, DOACs DO NOT require routine INR or PT monitoring (choice 1 is wrong) and have NO dietary vitamin K interactions (choice 3 is wrong). Doubling missed doses (choice 4) is dangerous and is incorrect for any anticoagulant; standard guidance is to take the missed dose if remembered within 6 hours, otherwise skip and resume the next scheduled dose.
In-depth explanation
DOACs include apixaban (Eliquis), rivaroxaban (Xarelto), edoxaban (Savaysa), and dabigatran (Pradaxa). They inhibit Factor Xa (apixaban, rivaroxaban, edoxaban) or thrombin (dabigatran). Compared with warfarin they offer predictable pharmacokinetics, no INR monitoring, no dietary vitamin K interaction, fewer drug interactions, and fixed dosing. Apixaban patient teaching: take twice daily, observe bleeding precautions, report unusual bruising, dark or tarry stools, hematuria, severe headache, or dizziness, hold before dental and surgical procedures per provider (typically 24 to 48 hours), and know that the reversal agent andexanet alfa is available for life-threatening bleeding. Missed-dose guidance for apixaban is to take the missed dose if remembered within 6 hours of the scheduled time and otherwise to skip and resume at the next scheduled dose; never double up. Compare with warfarin (skip if more than half a day late) and dabigatran (skip if within 6 hours of the next dose).
For study reference only. Always follow current clinical guidelines and your institution’s protocols.